Hikma Buys Teligent Assets To Expand Into Canada
Deal Worth $46m For Canadian Sterile Injectable Assets Follows Teligent Bankruptcy
Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.
You may also be interested in...
Hikma has the financial firepower and appetite to maintain its current deal-making momentum following several key transactions over the past year, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview, while also detailing how the firm plans to build up its US biosimilars business.
Hikma says it is now ranked second only to Pfizer in terms of US generic injectables volumes – overtaking rival Fresenius – as it continues to expand in the segment, including via recent acquisitions. Meanwhile, the firm is also laying the groundwork for a US biosimilars business.
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.